Trial · NCT07912541
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Major adverse cardiac events (MACE) - defined as composite of cardiovascular death, non-fatal myocardial infarction (MI), and clinically driven target vessel revascularization (CD-TVR) | 180 days | |
| Secondary | Incidence of Major Advance Cardiac Events 1. Cardiac Death 2. Non- fatal Myocardial Infarction 3. Clinically driven Target Vessel Revascularization | 30 and 360 days | |
| Secondary | Clinically driven target lesion revascularization (CD-TLR) | 30, 180 and 360 days | |
| Secondary | Target vessel failure (TVF) | 30, 180 and 360 days | a composite of Cardiovascular (CV) death, TV-MI and CD-TVR, and individual components of composite end points |
| Secondary | Non-Target Vessel related Myocardial Infarction | 30, 180, and 360 days | |
| Secondary | Stent thrombosis | 0-24 hours, 24 hours-30 days and late 30-365 days | Stent thrombosis as per 1. Academic Research Consortium \[ARC\] 2 Evidence definitions - Definite and probable. 2. As per latency - Acute (0-24 hours), Subacute (24 hours- 30 days) and late (30-365 days) |
| Secondary | Device success | 0 hour, 24 hours, 3 days | Defined as achievement of a final residual stenosis of \<20%, Successful deployment of stent with complete retrieval of delivery system without coronary dissection, device deformation \& visible mal apposition on fluoroscopy with stent boost |
| Secondary | Procedural Success | 0 hour, 24 hours, 3 days | Defined as achievement of a final diameter stenosis of \< 20%(site reported) using any PCI method, without the occurrence of death, MI, or repeat target vessel revascularization during hospital stay. |
| Secondary | Lesion success | 0 hour, 24 hours, 3 days | Defined as achievement of \< 20% residual stenosis using any percutaneous method. |
| Other | QCA Endpoints | 0 and 180 days | Late Lumen Loss |
| Other | QCA Endpoints | 0 and 180 days | Angiographic binary restenosis |
| Other | QCA Endpoints | 0 and 180 days | In-stent and in-segment minimum lumen diameter (MLD) |
| Other | QCA Endpoints | 0 and 180 days | In-stent and in-segment % diameter stenosis (DS) |
| Other | OCT Endpoints | 0 and 180 days | Minimal Lumen Area (MLA) |
| Other | OCT Endpoints | 0 and 180 days | Late lumen loss (LLL) |
| Other | OCT Endpoints | 0 and 180 days | Percentage area stenosis |
| Other | OCT Endpoints | 0 and 180 days | Neointimal hyperplasia |
| Other | OCT Endpoints | 0 and 180 days | proportion of in stent and in segment binary restenosis |
| Other | OCT Endpoints | 0 and 180 days | Proportion of struts uncovered and malapposed |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07912541/registered